Hyperfine (NASDAQ:HYPR – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
Profitability
This table compares Hyperfine and Sanara MedTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -210.75% | -97.88% | -61.81% |
| Sanara MedTech | -29.15% | 29.72% | 2.84% |
Volatility & Risk
Hyperfine has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Hyperfine and Sanara MedTech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 0 | 2.40 |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
Hyperfine currently has a consensus price target of $2.03, suggesting a potential upside of 160.65%. Sanara MedTech has a consensus price target of $35.00, suggesting a potential downside of 0.26%. Given Hyperfine’s stronger consensus rating and higher probable upside, analysts plainly believe Hyperfine is more favorable than Sanara MedTech.
Institutional & Insider Ownership
15.0% of Hyperfine shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Hyperfine and Sanara MedTech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $16.54 million | 5.00 | -$35.57 million | ($0.38) | -2.05 |
| Sanara MedTech | $103.12 million | 3.13 | -$37.56 million | ($3.59) | -9.77 |
Hyperfine has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Summary
Hyperfine beats Sanara MedTech on 8 of the 14 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
